Pilot genome-wide association study of antibody response to inactivated SARS-CoV-2 vaccines

Front Immunol. 2022 Nov 14:13:1054147. doi: 10.3389/fimmu.2022.1054147. eCollection 2022.

Abstract

Vaccines are a key weapon against the COVID-19 pandemic caused by SARS-CoV-2. However, there are inter-individual differences in immune response to SARS-CoV-2 vaccines and genetic contributions to these differences have barely been investigated. Here, we performed genome-wide association study (GWAS) of antibody levels in 168 inactivated SARS-CoV-2 vaccine recipients. A total of 177 SNPs, corresponding to 41 independent loci, were identified to be associated with IgG, total antibodies or neutral antibodies. Specifically, the rs4543780, the intronic variant of FAM89A gene, was associated with total antibodies level and was annotated as a potential regulatory variant affecting gene expression of FAM89A, a biomarker differentiating bacterial from viral infections in febrile children. These findings might advance our knowledge of the molecular mechanisms driving immunity to SARS-CoV-2 vaccine.

Keywords: COVID-19; GWAS; SARS-CoV-2; SNP; antibody; vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibody Formation
  • COVID-19 Vaccines*
  • COVID-19* / prevention & control
  • Child
  • Genome-Wide Association Study
  • Humans
  • Pandemics
  • SARS-CoV-2

Substances

  • COVID-19 Vaccines